Acute lymphoblastic leukaemia develops in both children and adults, with a peak incidence
between 1 year and 4 years. Most acute lymphoblastic leukaemia arises in healthy …

Acute lymphoblastic leukaemia occurs in both children and adults but its incidence peaks
between 2 and 5 years of age. Causation is multifactorial and exogenous or endogenous …

Minimal residual disease prior to allogeneic hematopoietic cell transplantation has been
associated with increased risk of relapse and death in patients with acute myeloid leukemia …

With steadily improved cure rates for children with newly diagnosed acute lymphoblastic
leukaemia (ALL), treating relapsed ALL has become increasingly challenging largely due to …

Diagnosis, treatment, response monitoring, and outcome of pediatric acute myeloid
leukemia (AML) have made enormous progress during the past decades. Because AML is a …

Minimal residual disease (MRD) before myeloablative hematopoietic cell transplantation
(HCT) is associated with adverse outcome in acute myeloid leukemia (AML) in first complete …

The most common cause of treatment failure in childhood acute lymphoblastic leukemia
(ALL) remains relapse, occurring in∼ 15%-20% of patients. Survival of relapsed patients …

Allogeneic hematopoietic stem cell transplantation (allo-SCT) remains the therapeutic
method with the most potent anti-leukemic activity mediated by the graft versus leukemia …

Disease overview Acute myeloid leukemia (AML) results from accumulation of abnormal
blasts in the marrow. These cells interfere with normal hematopoiesis, can escape into the …

Patients with B-lineage acute lymphoblastic leukemia (ALL) are at high-risk for relapse after
allogeneic hematopoietic cell transplantation (HCT). We conducted a single-center phase 2 …